Associated tags: Muscular dystrophy, Dystrophy, ALS, MDA, Research, Muscular Dystrophy Association, Neuromuscular disease, Pharmaceutical industry, Degenerative disease, Doctor of Philosophy, Patient
Locations: UNITED STATES, POMPE, MISSOURI, TX, WASHINGTON, SC, MN, NEW YEAR, FORT LAUDERDALE, RARE, FL, DC, ROME, CHICAGO, IL, US, NEW YORK
Life,
Volunteering,
Muscular Dystrophy Association,
Harley-Davidson,
Community engagement,
Muscular dystrophy,
Biogen,
General Motors,
National Association,
NALC,
Neuromuscular disease,
MDA,
Creativity,
Magic,
Counselor,
Summer camp,
Tourism New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.
Key Points:
- New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.
- MDA Summer Camp serves children and young adults ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.
- Last summer, more than 800 campers attended MDA Summer Camp, with nearly 600 volunteers.
- As is the case every year, MDA Summer Camp is offered on a first-come, first-served basis at no cost to participants.
Muscular Dystrophy Association,
Conference,
SPSMA,
Family,
Culture,
Neuromuscular disease,
Caregiver,
Muscular dystrophy,
Research,
Disability,
MDA,
Hope,
Parent,
University,
Empowerment,
SMA,
Bethlem myopathy,
Human,
Motivation,
Volunteering,
Social media,
Environment,
Nursing New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) has selected 39-year-old Ira Walker from Fort Lauderdale, Florida, as its 2024 MDA National Ambassador.
Key Points:
- New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) has selected 39-year-old Ira Walker from Fort Lauderdale, Florida, as its 2024 MDA National Ambassador.
- Walker joins 16-year-old National Ambassador Leah Zelaya from Brooklyn, New York, who continues her second year representing the organization.
- “It is my honor to accept the role as Muscular Dystrophy Association’s National Ambassador in 2024.
- MDA National Ambassadors play an integral role in furthering the mission of the Muscular Dystrophy Association to accelerate research, advance care, and empower the families we serve through their unique voices and perspectives.
Retrieved on:
Thursday, December 21, 2023
New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising for the leading voluntary health organization in the U.S. for people living with muscular dystrophy, ALS (also known as Lou Gehrig’s disease), and related neuromuscular diseases.
Key Points:
- New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising for the leading voluntary health organization in the U.S. for people living with muscular dystrophy, ALS (also known as Lou Gehrig’s disease), and related neuromuscular diseases.
- The collaboration began in 1985 with Acosta, an Acosta Group sales agency.
- Hank Lautrup, an Acosta associate whose son lived with muscular dystrophy, is credited with the early development of the relationship with MDA.
- I want to thank everyone at Acosta Group – all the donors, volunteers, ambassadors, employees, customers, and community members who have participated in achieving this incredible $100 million milestone.
Retrieved on:
Monday, December 18, 2023
Research,
Muscular Dystrophy Association,
Gene,
Friedreich's ataxia,
Myasthenia gravis,
Citgo,
ALS,
MDA,
Muscular dystrophy,
CITGO,
Duchenne muscular dystrophy,
Pompe HOUSTON, Dec. 18, 2023 /PRNewswire/ -- CITGO Petroleum Corporation concluded another successful fundraising year with more than $2.9 million raised for the Muscular Dystrophy Association's (MDA) mission for families living with muscular dystrophy, ALS and related neuromuscular diseases.
Key Points:
- HOUSTON, Dec. 18, 2023 /PRNewswire/ -- CITGO Petroleum Corporation concluded another successful fundraising year with more than $2.9 million raised for the Muscular Dystrophy Association's (MDA) mission for families living with muscular dystrophy, ALS and related neuromuscular diseases.
- Funds raised will be used towards accelerating research, advancing multidisciplinary care, and advocating for inclusion, access and equity for the neuromuscular community.
- and Corpus Christi, Texas set new fundraising records, raising more than $970,000, $500,000 and $645,000 respectively.
- CITGO is a cherished partner in the progress we are making to empower families to live longer more independent lives."
Retrieved on:
Wednesday, November 1, 2023
Smoke,
Cricket,
Scotchman,
GPM Investments,
Holiday,
MDA,
Muscular dystrophy,
Family,
Grand Prix,
Muscular Dystrophy Association,
Research,
Investment,
ALS,
Admiral,
GPM,
Chimney,
VPS Convenience,
Associated Wholesale Grocers,
Fast fuel system,
Circle K,
Neuromuscular disease,
Drink,
Investment company,
Grocery store,
Pride New York, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched its largest Holiday Retail Campaign to fundraise in thousands of retail locations nationwide from November through January 2024.
Key Points:
- New York, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched its largest Holiday Retail Campaign to fundraise in thousands of retail locations nationwide from November through January 2024.
- Retailers invite customers to participate in the MDA Holiday campaign by donating at checkout or rounding up their purchase.
- Donations made by customers will be displayed on special MDA Holiday pinups in each location, showing support for MDA families.
- “The generous partners supporting our annual MDA Holiday Retail Campaign are part of our family at the Muscular Dystrophy Association.
MTPA,
MDA,
American Opportunity Tax Credit,
Muscular Dystrophy Association,
Data collection,
Finger,
Drug development,
ALS,
Patient,
Doctor of Philosophy,
Medical imaging,
Fitbit New York, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) and Mitsubishi Tanabe Pharma America, Inc .
Key Points:
- New York, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) and Mitsubishi Tanabe Pharma America, Inc .
- (MTPA) today announced their collaboration for a remote observational research study focusing on amyotrophic lateral sclerosis (ALS) .
- The newly developed research study, ALS Go-Digital, is designed to pair digital data collected remotely with longitudinal clinical data.
- “We are excited to be collaborating with Mitsubishi Tanabe Pharma America on this important study,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
Retrieved on:
Thursday, October 26, 2023
Steroid,
Principal,
FDA,
Duke University Hospital,
Research,
University,
NF-κB,
Dean (education),
Associate,
Duke University,
MDA,
Diversified Pharmaceutical Services,
Muscular Dystrophy Association,
Binghamton University,
Medical director,
Rare disease,
Weight gain,
US Food Sovereignty Alliance,
Doctor of Philosophy,
Catalyst Pharmaceuticals,
Vamorolone,
Pediatrics,
Disease,
Clinical trial,
Duchenne,
Duchenne muscular dystrophy,
DMD,
Investment,
Patient,
Griffin,
Bone density,
Pharmaceutical industry,
Nursing New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
Key Points:
- New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
- This multi-functional drug shows potent inhibition of pro-inflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties.
- This novel therapy, supported in part by MDA Venture Philanthropy, demonstrates similar efficacy to traditional corticosteroids with reduced negative downstream impacts or side effects.
- “My son was diagnosed with Duchenne muscular dystrophy, and he was the first person dosed with vamorolone right before his 7th birthday.
Retrieved on:
Wednesday, October 18, 2023
GMG,
FDA,
UCB,
University,
MDA,
Muscular Dystrophy Association,
Physician,
US Foods,
News,
Pediatrics,
Eyelid,
Disease,
Acetylcholine receptor,
Patient,
Doctor of Philosophy,
Associate,
Agonal respiration,
Pharmaceutical industry New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Key Points:
- New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
- Zilucoplan is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG, and it is the only once-daily gMG-target therapy for self-administration.
- "The recent approval of zilucoplan is great news for people living with gMG,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
- “This is the second gMG therapy out of UCB that has achieved FDA approval this year, providing patients and physicians with important options.
Retrieved on:
Thursday, September 28, 2023
Duke University,
US Food Sovereignty Alliance,
University,
Pediatrics,
Doctor of Philosophy,
Public policy,
B cell,
Glycogen storage disease type II,
Medicine,
Associate,
Science,
Capsule,
ERT,
Patient,
Muscular Dystrophy Association,
Blood,
Amicus Therapeutics,
MDA,
FDA,
Enzyme replacement therapy,
Pharmaceutical industry,
Cipaglucosidase alfa New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease (LOPD).
Key Points:
- New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease (LOPD).
- Pombiliti™ + Opfolda™ will be made available and marketed in the United States by Amicus Therapeutics.
- Pombiliti™ + Opfolda™ is a novel two-component therapy consisting cipaglucosidase alfa-atga, a long-term enzyme replacement therapy (ERT), and miglustat, an oral enzyme stabilizer.
- "We are extremely pleased with the recent approval of Pombiliti and Opfolda,” said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.
Retrieved on:
Wednesday, September 13, 2023
Muscular dystrophy,
Mir-126,
Muscular Dystrophy Association,
SMA,
SMN,
University,
Duchenne muscular dystrophy,
EDMD,
DM,
Grant,
Doctor of Philosophy,
Barrier,
DM1,
University of Zurich,
Johns Hopkins School of Medicine,
Columbia University Irving Medical Center,
Tel Aviv University,
Emery–Dreifuss muscular dystrophy,
University of Iowa,
Prognosis,
Research,
Mentorship,
Charcot–Marie–Tooth disease,
RNA,
CMT,
Duchenne,
Facial muscles,
Glycogen storage disease type II,
Student,
University of Rochester,
Neuromuscular disease,
DMD,
Patient,
Regents of the University of Michigan,
Diagnosis,
Growth,
Regent,
B cell,
Health,
MDA,
FDA,
Mobile app,
ALS,
Myotonic dystrophy,
LGMD,
Disease,
Pharmaceutical industry,
Medical device,
Nursing,
Exercise New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.
Key Points:
- New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.
- The newly funded projects aim to advance research discoveries and new therapy development in multiple areas including amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), spinal muscular atrophy (SMA), myotonic dystrophy (DM), and many more.
- “The Muscular Dystrophy Association has consistently been a leader in advancing treatments for people living with muscular dystrophy, ALS and related neuromuscular diseases,” said Donald S. Wood, Ph.D., President and CEO, Muscular Dystrophy Association.
- Internship recipients and mentors included:
These are just a few of the many grants the Muscular Dystrophy Association has pledged to support.
